"Rising Concerns: JN.1 Variant Impact and COVID-19 Resurgence"
TL;DR
Andrea Garcia, Vice President of Science, Medicine and Public Health at the American Medical Association, discusses the surge in respiratory viruses, including flu, RSV, and COVID, with flu cases expected to peak by the end of the month. The JN.1 COVID variant is responsible for 61% of cases in the U.S., leading to increased hospitalizations and deaths. Low uptake of Paxlovid, despite its effectiveness in preventing deaths and hospitalizations, is a concern, while a study suggests that hydroxychloroquine may have caused nearly 17,000 deaths during the first wave of the pandemic.
- Symptoms of new COVID variant JN.1, latest studies on Paxlovid rebound and hydroxychloroquine American Medical Association
- What to know about JN.1, the latest COVID-19 variant WTOP
- Has JN.1 made home COVID tests less effective? Here's what we know San Francisco Chronicle
- Newest COVID-19 variant driving up cases across the country LOCAL 12
- UK: Experts warn of another Covid wave in the UK by next week WION
Want the full story? Read the original reporting
Read on American Medical Association